Addressing Key limitations of Interleukins
The National Cancer Institute ranks certain interleukins (IL12, IL15, IL2) as top cancer targets, however, their therapeutic utility has some key limitations:
Bi-specific biologic drugs are actively being pursued as the next generation of immunotherapies. Sonnet’s versatile platform has been demonstrated to improve delivery of the active drug(s) to the tumor, as well as to help overcome past challenges with cytokine-based treatments, which are powerful tools in improving immunotherapy response rates.
Checkpoint inhibitors are the cornerstone of current cancer immunotherapy. These antibody-based approaches can be very effective when the patient’s immune response to a tumor has been activated. However, adequate activation does not occur in the majority of patients. To reach their potential, checkpoint inhibitors will need other agents to help activate the immune response; cytokines are a proven method for doing so. By addressing past challenges here, Sonnet aspires to unleash the true potential of checkpoint inhibition treatments.
We have developed a proprietary Fully Human Albumin Binding construct (FHAB) with the following key features:
Our proof-of-concept data demonstrates the following improvements for interleukin therapies: